Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AF04 STAVUDINUM CAPS. 15 mg
ZERIT 15 mg 15 mg BRISTOL-MYERS SQUIBB
PHARMA EEIG
J05AF04 STAVUDINUM CAPS. 20 mg
ZERIT 20 mg 20 mg BRISTOL-MYERS SQUIBB
PHARMA EEIG
J05AF04 STAVUDINUM CAPS. 30 mg
ZERIT 30 mg 30 mg BRISTOL-MYERS SQUIBB
PHARMA EEIG
J05AF04 STAVUDINUM CAPS. 40 mg
ZERIT 40 mg 40 mg BRISTOL-MYERS SQUIBB
PHARMA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 613 |J05AF05| LAMIVUDINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AF05 LAMIVUDINUM COMPR. FILM. 100 mg
ZEFFIX 100 mg 100 mg GLAXO GROUP LTD.
J05AF05 LAMIVUDINUM SOL. ORALA 10 mg/ml
EPIVIR 10 mg/ml 10 mg/ml GLAXO GROUP LTD.
J05AF05 LAMIVUDINUM COMPR. FILM. 150 mg
EPIVIR 150 mg 150 mg GLAXO GROUP LTD.
J05AF05 LAMIVUDINUM SOL. ORALA 5 mg/ml
ZEFFIX 5 mg/ml 5 mg/ml GLAXO GROUP LTD.
________________________________________________________________________________
______________________________________________________________________________
| 614 |J05AF06| ABACAVIRUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul infecţiei HIV la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.
Dostları ilə paylaş: | 
